glp-1 small molecule agonist Receptor Agonists A Small-Molecule Oral Agonist of
Description
Most recently, the Exenatide-PD3 phase III trial failed to show any advantage in motor or nonsymptoms over placebo (61), and questions remain about whether a subgroup of patients with PD may be more likely to respond to this therapy
A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol
The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity
Accessed October 2025
This increased activation was correlated with clinical improvements in PD symptoms
